Caribou Biosciences Has $94.8 Million Left As It Weighs A Merger Or Liquidation
The company plans to halt development of both cancer therapies after financing became harder to secure.
Caribou Biosciences, which develops donor-cell therapies for blood cancers, ended September with $94.8 million in cash and investments, versus $142.8 million at year-end 2025, according to its Thursday earnings release, furnished with an SEC filing. The company is weighing options including a merger or liquidation and plans to stop development of its two cancer-treatment candidates.
Financing Forces A Development Retreat
The strategic review accompanies a restructuring approved by Caribou’s board and announced on October 6. Caribou said the financing environment for donor-derived CAR-T therapies had made raising the money needed to advance vispa-cel and CB-011 increasingly difficult.
The plan calls for ending the candidates’ clinical trials and further development, substantially reducing staff and cutting other costs. Potential outcomes include a merger, acquisition, business combination, transactions involving Caribou’s assets, or dissolution and liquidation.
The retreat follows an April 2025 workforce cut of 47 employees, about 32%, intended to concentrate the business on those same candidates.
Lower Costs, Continuing Losses
Caribou’s third-quarter net loss was $26.6 million, or $0.25 per share, compared with $27.5 million, or $0.30 per share, a year earlier. Revenue from licensing and other third-party agreements fell to $1.6 million from $2.2 million.
Research and development spending totaled $21.3 million, versus $22.4 million in the prior-year quarter. Administrative expenses fell to $7.9 million from $9.2 million. The operating loss was $27.642 million, compared with $29.400 million.
For the first nine months of 2026, Caribou lost $75.979 million, versus $121.637 million a year earlier. Research spending for that period fell to $60.902 million from $85.624 million, while administrative expenses declined to $23.862 million from $29.335 million. The earlier period also included $12.150 million in operating impairment charges and a $9.158 million equity-investment impairment.
Stockholders’ equity stood at $76.633 million at September 30, compared with $122.175 million at December 31, 2025. Total liabilities were $46.393 million, versus $53.192 million.
Two Cancer Programs Face A Halt
Caribou uses its chRDNA CRISPR genome-editing technology to build off-the-shelf CAR-T treatments from healthy donors’ cells, rather than making a treatment from each patient’s own cells. The company has no medicines approved for sale.
Vispa-cel targets CD19 in B cell non-Hodgkin lymphoma that has returned or resisted treatment. The company said it had reached agreement with the FDA on the design of a late-stage trial. CB-011 targets BCMA in multiple myeloma that has returned or resisted treatment.
Both candidates have received FDA Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug designations. Those regulatory designations sit alongside the company’s plan to discontinue the programs as it pursues strategic alternatives.
Caribou’s review includes the possibility of ending the company through dissolution and liquidation, alongside transactions that could transfer the business or its assets.
Sources
- 8-K Filing — Caribou Biosciences, Inc. (CRBU) — SEC EDGAR
- Exhibit crbu-20261105xexx991.htm — Caribou Biosciences, Inc. 8-K exhibit — SEC EDGAR
- Caribou Biosciences Announces Presentations at the 2026 — globenewswire.com
